Can a pill reverse heart scarring? new study aims to find out
NCT ID NCT07583173
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug finerenone can reduce scarring in the heart muscle and improve heart structure and function in people with heart failure. About 104 adults with mild to moderate heart failure will receive either finerenone or a placebo for 6 months. The main goal is to see if finerenone reduces a measure of heart scarring called extracellular volume, as seen on MRI scans.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Beijing, 100037, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Could continuing a common heart drug before surgery save lives?
- Poles apart? nordic walking may outpace standard rehab for heart failure
- Could a gentler tug on the Heart's reins spark recovery?
- Can slow breathing soothe a failing heart?
- Can shedding pounds reboot the Heart's exercise engine?